Futura Medical CSD500 CE Mark Certification

Published: Jun 20, 2011

June 20, 2011 -- Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce it has been informed that the relevant Notified Body is satisfied that all outstanding points in the regulatory dossier for CSD500 have been resolved and has been recommended to their Review Panel for approval. The Panel’s approval process typically takes a month and is already underway. A further statement will be made in the coming weeks regarding the issue of the CE mark certificate.

The CE mark certificate will enable CSD500 to be marketed and sold within 29 European territories and a number of other non-European territories that recognise the CE mark process. Reckitt Benckiser plc, makers of the Durex® branded condom have exclusive global rights to CSD500.

For any further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.com


Nomura Code Securities Limited

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

Buchanan Communications

Mark Court / Jessica Fontaine

Tel: +44 (0) 20 7466 5000

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.


Back to news